HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
HC Wainwright & Co.重申對Milestone Pharmaceuticals的買入評級,維持25美元的目標價格。
HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $25 price target.
HC偉凱證券的分析師Patrick Trucchio將milestone pharmaceuticals(納斯達克:MIST)評爲買入,維持25美元的目標價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。